NASC (Nascent Pharma Holdings) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 06, 2026)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.02
View Full Analysis

What is Nascent Pharma Holdings 5-Year Yield-on-Cost %?

Nascent Pharma Holdings NASC -0.01% 12 5-Year Yield-on-Cost % is 0.00 as of Jul. 06, 2026. GuruFocus rates NASC with a GF Score™ of 12/100.

Nascent Pharma Holdings's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Nascent Pharma Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



NASC's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.265
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Nascent Pharma Holdings  (OTCPK:NASC) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Nascent Pharma Holdings 5-Year Yield-on-Cost % Related Terms

NASC vs ALID, CPMD, PLSH: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nascent Pharma Holdings 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's 5-Year Yield-on-Cost % falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Nascent Pharma Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Nascent Pharma Holdings (NASC) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' 5-Year Yield-on-Cost % too high?
Nascent Pharma Holdings' current 5-Year Yield-on-Cost % is 0.00. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' 5-Year Yield-on-Cost % compare to ALID and CPMD?
Nascent Pharma Holdings' 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 5-Year Yield-on-Cost % is 2.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nascent Pharma Holdings and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Pharma Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price